Patents by Inventor Cyril Privezentzev

Cyril Privezentzev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE
    Publication number: 20230406935
    Abstract: The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Application
    Filed: December 8, 2022
    Publication date: December 21, 2023
    Applicant: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • FC binding fragments comprising a PD-L1 antigen-binding site
    Patent number: 11548948
    Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 10, 2023
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE
    Publication number: 20210139590
    Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 13, 2021
    Applicant: F-STAR BETA LIMITED
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • CTLA-4 Variants
    Publication number: 20180208639
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: December 21, 2017
    Publication date: July 26, 2018
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • CTLA-4 variants
    Patent number: 9884902
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 6, 2018
    Assignee: MedImmune Limited
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev
  • CTLA-4 Variants
    Publication number: 20150104450
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Application
    Filed: March 11, 2013
    Publication date: April 16, 2015
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev